Neurogene Inc. (NGNE)
NGM · Healthcare · Biotechnology
$29.10
+0.34%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$459.8M
Shares Outstanding
15.8M
Exchange
NGM
Currency
USD
About Neurogene Inc.
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -26.1M | -23.8M | -27.5M | -33.3M |
| Net Income | -22.0M | -21.0M | -24.7M | -30.9M |
| Diluted EPS | $-1.05 | $-0.99 | $nan | $-1.39 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 925K | 0.00 |
| Operating Income | -56.5M | -55.6M | -82.6M | -103.3M |
| Net Income | -55.2M | -36.3M | -75.1M | -90.4M |
| Diluted EPS | $-37.80 | $-73.83 | $-4.28 | $nan |